Futura Medical Share News (FUM)

IN BRIEF: Futura Medical's ED treatment approved in Saudi Arabia

Futura Medical PLC - Surrey, England-based pharmaceutical company - Says its distribution partner, Labatec Pharma, received regulatory approval for MED3000 in Saudi Arabia. MED3000 is Futura's topical, gel-based erectile dysfunction treatment. Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon, with initial launch planned in the final quarter of 2023. Adds the manufacturing of Eroxon for launch has been completed.

Futura Medical chair steps down, promotes non-executive director

(Alliance News) - Futura Medical PLC on Tuesday said it appointed Non-Executive Chair Jeff Needham as the successor to outgoing chair John Clarke, who has stepped down.

Futura Medical agrees US licensing deal with Haleon for Med3000 gel

(Alliance News) - Futura Medical PLC on Monday said it agreed a licensing deal with Haleon PLC for the rights to exclusively commercialise Futura's erectile dysfunction treatment Med3000 in the US.

Futura Medical shares rise on ED licensing deal with Haleon

(Sharecast News) - Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.

IN BRIEF: Futura Medical hails continued momentum after Eroxon launch

Futura Medical PLC - Guildford, Surrey-based pharmaceutical company - Says it is encouraged by the early growth trajectory of erectile dysfunction treatment gel Eroxon following its recent launch. "Both initial orders of Eroxon by our partners and in-market demand have been in line with our expectations and should continue to build as partners expand sales channels, numbers of outlets and new geographies," it adds. Predicts that net revenue for the six months ending June 30 will be no less than GBP1.5 million. Says momentum continues to build as it enters the commercialisation phase and positions itself to receive its first significant revenue in 2023. It previously in April said that its 2022 pretax loss widened to GBP6.9 million from GBP5.8 million the year before.

UK shareholder meetings calendar - next 7 days